Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0000902664-25-004410
Filing Date
2025-10-15
Accepted
2025-10-15 06:50:13
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 8730
2 STOCK PURCHASE AGREEMENT p25-2183exhibiti.htm EX-99.I 88898
  Complete submission text file 0000902664-25-004410.txt   99301
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91484 | Film No.: 251393384
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 3503 WILD CHERRY DRIVE BUILDING 9 AUSTIN TX 78738
Business Address 3503 WILD CHERRY DRIVE BUILDING 9 AUSTIN TX 78738 512-254-3790
ADAR1 Capital Management, LLC (Filed by) CIK: 0001940272 (see all company filings)

EIN.: 000000000 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13D/A